What this study is
Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis.
What's being tested
- Fight Fatigue
Intervention · BEHAVIORAL
Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.
- Attention Control
Intervention · OTHER
End-stage kidney disease education
Study details
- Sponsor
- University of Illinois at Chicago
- Conditions
- End Stage Renal Disease on Dialysis
- Enrolling
- 40 people
- Starts
- 2025-09-02
- Est. completion
- 2027-06
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Diagnosis of ESKD diagnosis and receiving hemodialysis for at least 3 months
- Can read and speak English
- Fatigue measured via visual analogue scale, score ≥4 over the last week
- Able to stand and walk one block
- Has a cell phone that can receive text messages
You can't join if
- Patient's nephrologist refuses for them to participate
- Unstable angina
- Unstable pulmonary disease or pulmonary symptoms that preclude participation
- Lower-extremity amputation without prosthetic (BKA, AKA) -Orthopedic or neurologic condition that would preclude walking or tensing/releasing of muscles-
- Cognitive impairment that, in the judgement of the research team, precludes trial participation
- Participation in the formative phase of the development of Fight Fatigue
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUI Health/University of Illinois Chicago
Chicago, Illinois, United States
- Mary Hannan · Contact312-355-4838mhanna22@uic.edu
Recruiting
Study team
Sponsor
University of Illinois at Chicago
Study ID STUDY2025-0281
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.